Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials
Clin Lymphoma Myeloma Leuk. 2025 Jan 25:S2152-2650(25)00024-2.…
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT
Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02524-2.…
Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma
Blood Cancer Discov. 2025 Feb 6. doi: 10.1158/2643-3230.BCD-24-0178.…
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care
Front Immunol. 2025 Jan 7;15:1512154. doi: 10.3389/fimmu.2024.1512154.…
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Blood. 2025 Jan 10:blood.2024026830. doi: 10.1182/blood.2024026830.…
Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas
Bone Marrow Transplant. 2024 Dec 14. doi: 10.1038/s41409-024-02496-9.…
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Hemasphere. 2024 Dec 10;8(12):e70031. doi: 10.1002/hem3.70031.…
Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial
Hematol Oncol. 2025 Jan;43(1):e70000. doi: 10.1002/hon.70000.ABSTRACTA…
Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT
Bone Marrow Transplant. 2024 Nov 22. doi: 10.1038/s41409-024-02459-0.…
Glofit-GemOx: a new treatment paradigm in relapsed or refractory diffuse large B-cell lymphoma?
Lancet. 2024 Nov 16;404(10466):1899-1901. doi: 10.1016/S0140-6736(24)02138-X.NO…
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
J Hematol Oncol. 2024 Oct 29;17(1):102. doi: 10.1186/s13045-024-01608-8.ABSTRACTChimeric…
Promoting Equitable and Affordable Patient Access to Safe and Effective Innovations in Donation and Transplantation of Substances of Human Origin and Derived Therapies
Transplantation. 2024 Oct 22. doi: 10.1097/TP.0000000000005169.…
